Basel Medical Group Ltd Ordinary Shares

NextCure shares surged more than 200% on Tuesday after the company announced a definitive all-stock merger agreement with privately held Avere Therapeutics. The combined company will operate as Avere Therapeutics and trade on Nasdaq under the ticker AVRX, with the deal expected to close in the second half of 2026. Avere's lead program, AVR-001, is an oral IL-23 receptor antagonist with Phase 1b psoriasis data, and a Phase 2b study is set to begin in early 2027. Other notable biotech gainers included Basel Medical Group, which rose over 26% after regaining Nasdaq compliance, and Outlook Therapeutics, up more than 11% ahead of a July 29 FDA decision on its wet AMD treatment ONS-5010.

Basel Medical Group Ltd has regained compliance with the Nasdaq minimum bid price requirement. The company received notification from Nasdaq confirming that its ordinary shares maintained a closing bid price of at least $1.00 per share for the last 10 consecutive business days, from June 23, 2026 to July 7, 2026. This follows a January 22, 2026 notice from Nasdaq that the shares had failed to meet the $1.00 minimum bid price over the prior 30 consecutive business days. With the recent price recovery, the company now satisfies Listing Rule 5550(a)(2).